Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Virology

• Publication date

  2009-06-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.00280-09PMID 19494014PMCID PMC2715790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Level of APOBEC3G (hA3G)-Related G-to-A Mutations Does Not Correlate with Viral Load in HIV Type 1-Infected Individuals

  2008cited by this paper
• Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.

  2008cited by this paper
• Small-molecule inhibition of HIV-1 Vif

  2008cited by this paper
• APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts

  2008cited by this paper
• Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41

  2008cited by this paper
• The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction

  2008influential reference
• Retrovirology BioMed Central Review HIV-1 Vif, APOBEC, and Intrinsic Immunity

  2008cited by this paper
• The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

  2008cited by this paper
• Human Immunodeficiency Virus (HIV) Type 1 Proviral Hypermutation Correlates with CD4 Count in HIV-Infected Women from Kenya

  2008influential reference
• Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors

  2007cited by this paper
• APOBEC-mediated viral restriction: not simply editing?

  2007influential reference
• Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection

  2007cited by this paper
• Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation

  2007influential reference
• Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1

  2007influential reference
• Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.

  2006cited by this paper
• APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA

  2006cited by this paper
• Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination

  2006influential reference
• Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy.

  2006cited by this paper
• Quantification of Genital Human Immunodeficiency Virus Type 1 (HIV-1) DNA in Specimens from Women with Low Plasma HIV-1 RNA Levels Typical of HIV-1 Nontransmitters

  2006cited by this paper
• Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation

  2006influential reference
• Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion

  2006cited by this paper
• Protecting APOBEC3G: a potential new target for HIV drug discovery.

  2005cited by this paper
• G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo

  2005cited by this paper
• A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.

  2005cited by this paper
• Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

  2005influential reference
• Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification

  2005cited by this paper
• A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.

  2005cited by this paper
• DNA Substrate Length and Surrounding Sequence Affect the Activation-induced Deaminase Activity at Cytidine*

  2004cited by this paper
• Lavreys L, Baeten JM, Kreiss JK, Richardson BA, Chohan BH, Hassan W, Panteleeff DD, Mandaliya K, Ndinya-Achola JO, Overbaugh J.Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in w

  2004cited by this paper
• Functional analysis of HIV-1 vif genes derived from Japanese long-term nonprogressors and progressors for AIDS.

  2004cited by this paper
• Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

  2004cited by this paper
• Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission.

  2004cited by this paper
• Retroviral restriction by APOBEC proteins

  2004cited by this paper
• Widespread Adaptive Evolution in the Human Immunodeficiency Virus Type 1 Genome

  2003cited by this paper
• Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

  2003cited by this paper
• MacClade 4: analysis of phy-logeny and character evolution

  2003cited by this paper
• The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

  2003cited by this paper
• The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

  2003cited by this paper
• HIV Type 1 Variants Transmitted to Women in Kenya Require the CCR5 Coreceptor for Entry, Regardless of the Genetic Complexity of the Infecting Virus

  2002cited by this paper
• Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.

  2001cited by this paper
• Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells

  2001cited by this paper
• Detecting hypermutations in viral sequences with an emphasis on G A hypermutation

  2000cited by this paper
• Evaluation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay Using Primary Subtype A, C, and D Isolates from Kenya

  2000cited by this paper
• Variants from the Diverse Virus Population Identified at Seroconversion of a Clade A Human Immunodeficiency Virus Type 1-Infected Woman Have Distinct Biological Properties

  1999cited by this paper
• Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1.

  1998cited by this paper
• Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

  1997cited by this paper
• The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

  1997influential reference
• Unimpaired function of a naturally occurring C terminally truncated vif gene product of human immunodeficiency virus type 1.

  1996cited by this paper
• Viral dynamics in human immunodeficiency virus type 1 infection

  1995cited by this paper
• Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes

  1992cited by this paper
• Interactive analysis of phylogeny and character evolution using the computer program MacClade.

  1989cited by this paper

• APOBEC3G Antagonism by Vif, or When Structure Meets Biological and Evolutionary Studies.

  2025cites this paper
• Persistent cell-associated HIV-1 RNA in virally suppressed individuals on INSTI-based ART

  2025cites this paper
• HIV-1 Vif global diversity and possible APOBEC-mediated response since 1980

  2024cites this paper
• Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction

  2024cites this paper
• Impact of misclassified defective proviruses on HIV reservoir measurements

  2023cites this paper
• Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Is Associated with Lower Levels of Defective HIV-1 Provirus

  2023cites this paper
• Differential activity of APOBEC3F, APOBEC3G, and APOBEC3H in the restriction of HIV-2.

  2021cites this paper
• Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.

  2019cites this paper
• Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice

  2019cites this paper
• Absence of A3Z3-Related Hypermutations in the env and vif Proviral Genes in FIV Naturally Infected Cats

  2018cites this paper
• CHARACTERIZATION OF APOBEC3 REPERTOIRES AND EFFECTS ON RETROVIRAL REPLICATION

  2018cites this paper
• ROLE OF APOBEC3 ENZYMES IN HIV-1 EVOLUTION

  2018cites this paper
• STUDIES ON THE MECHANISMS OF ANTI-HIV-1 FUNCTIONS OF APOBEC3F AND APOBEC3G

  2017cites this paper
• RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients

  2017cites this paper
• Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G

  2016cites this paper
• Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

  2016cites this paper
• HIV-2 Vif Diversity Among Defective and Nondefective Sequences

  2016cites this paper
• Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation

  2016cites this paper
• Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage

  2015cites this paper
• Extremely High Mutation Rate of HIV-1 In Vivo

  2015cites this paper
• High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients

  2015cites this paper
• Incomplete APOBEC 3 G / F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR 5 to CXCR 4 Usage

  2015cites this paper
• Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus

  2014cites this paper
• Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation

  2014cites this paper
• High Rates of Human Immunodeficiency Virus Type 1 Mutational Profiles by Single-Genome Amplification after 48-Hour Propagation in Peripheral Blood Mononuclear Cells at Different Levels of Cell Activation

  2014cites this paper
• Contribution of APOBEC3-Driven Mutagenesis to HIV Evolution and HIV Drug Resistance

  2014cites this paper
• The role of APOBEC3G in acute and early HIV-1 subtype C infection.

  2014cites this paper
• Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine in Primary T Lymphocytes to Affect Viral G-to-A Mutation Levels and Infectivity

  2014cites this paper
• In Vivo HIV-1 Hypermutation and Viral Loads Among Antiretroviral-Naive Brazilian Patients

  2014influential citation
• HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity

  2014cites this paper
• Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses

  2014cites this paper
• Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.

  2014cites this paper
• APOBEC3D and APOBEC3F Potently Promote HIV-1 Diversification and Evolution in Humanized Mouse Model

  2014cites this paper
• Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

  2014cites this paper
• AID and APOBECs span the gap between innate and adaptive immunity

  2014cites this paper
• Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition

  2014cites this paper
• APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study

  2013cites this paper
• The Role of Cytidine Deaminases on Innate Immune Responses against Human Viral Infections

  2013cites this paper
• Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches

  2013cites this paper
• The ancient and recurrent evolution of Apobec3 antiviral activity in primates

  2013cites this paper
• Human Immunodeficiency Virus Reverse Transcriptase

  2013cites this paper
• Correction: Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

  2013cites this paper
• APOBECs and Their Role in Proviral DNA Synthesis

  2013cites this paper
• Characterization of Circulating HIV Type 1 env Genes in Plasma of Two Antiretroviral-Naive Slow Progressing Patients with Broad Neutralizing Antibody Response with Evidence of Recombination

  2012cites this paper
• Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment

  2012cites this paper
• E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

  2012cites this paper
• Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n

  2012cites this paper
• APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome

  2012cites this paper
• Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

  2012cites this paper
• APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.

  2012influential citation
• APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

  2012cites this paper
• APOBEC3-Mediated Editing in HIV Type 1 from Pediatric Patients and Its Association with APOBEC3G/CUL5 Polymorphisms and Vif Variability

  2012cites this paper
• Running Loose or Getting Lost: How HIV-1 Counters and Capitalizes on APOBEC3-Induced Mutagenesis through Its Vif Protein

  2012cites this paper
• Contribution des protéines régulatrices Vif et Vpr du VIH-1 dans la résistance aux antirétroviraux chez des patients en échec virologique

  2012cites this paper
• The role of the rhesus macaque (macaca mulatta) apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) in lentiviral replication and persistence

  2012cites this paper
• Expression of APOBEC3G/3F and G-to-A Hypermutation Levels in HIV-1-Infected Children with Different Profiles of Disease Progression

  2011cites this paper
• Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1

  2011cites this paper
• The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G, APOBEC3F, and APOBEC3H

  2011cites this paper
• In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing.

  2011cites this paper
• Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms.

  2011cites this paper
• Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing

  2011cites this paper
• Adaptation of Subtype A Human Immunodeficiency Virus Type 1 Envelope to Pig-Tailed Macaque Cells

  2011cites this paper
• Cellular Restriction Factors: Exploiting the Body’s Antiviral Proteins to Combat HIV-1/AIDS

  2011cites this paper
• Cellular HIV-1 restriction factors: a new avenue for AIDS therapy?

  2010cites this paper
• Host proteins involved in HIV infection: new therapeutic targets.

  2010cites this paper
• HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

  2010cites this paper
• The interface between the innate interferon response and expression of host retroviral restriction factors.

  2010cites this paper
• Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics

  2010cites this paper
• Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

  2010cites this paper
• Remarkable Lethal G-to-A Mutations in vif-Proficient HIV-1 Provirus by Individual APOBEC3 Proteins in Humanized Mice

  2010cites this paper
• Identifying and characterizing recently transmitted viruses

  2010cites this paper
• Absence of Primary Integrase Resistance Mutations in HIV Type 1-Infected Patients in Venezuela

  2010cites this paper
• Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

  2009cites this paper
• MULTIPLE WAYS OF TARGETING APOBEC3/VIF INTERACTIONS FOR ANTI-HIV-1 DRUG DEVELOPMENT

  2009cites this paper